Overview

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Status:
Not yet recruiting
Trial end date:
2023-04-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC